Abstract Febuxostat is a xanthine oxidoreductase inhibitor that has been developed to treat chronic gout. In healthy subjects, the pharmacokinetic parameters of febuxostat after multiple oral dose administration include an oral availability of about 85 %, an apparent oral clearance (CL/F) of 10.5 ± 3.4 L/h and an apparent volume of distribution at steady state (V ss /F) of 48 ± 23 L. The time course of plasma concentrations follows a two-compartment model. The initial half-life (t ) is approximately 2 h and the terminal t determined at daily doses of 40 mg or more is 9.4 ± 4.9 h. Febuxostat is administered once daily. The maximum (peak) plasma concentrations are approximately 100-fold greater than the trough concentrations. Consequently, there is no significant accumulation of the drug during multiple dose administration. There are few data on the pharmacokinetics of febuxostat in patients with gout. While the pharmacokinetic parameters are not affected by mild to moderate hepatic impairment, there is no consensus on whether renal impairment has any effect on the pharmacokinetics of febuxostat. Febuxostat is extensively metabolised by oxidation (approximately 35 %) and acyl glucuronidation (up to 40 %); febuxostat acyl glucuronides are cleared by the kidney. In healthy subjects treated with multiple doses of febuxostat 10-240 mg, the concentrations of serum urate are reduced by a maximum of about 80 %. The percentage reduction in the concentrations of serum urate is slightly less in gouty patients than in healthy subjects.
Introduction
Febuxostat is an inhibitor of xanthine oxidoreductase (XOR) and has been developed to treat gout by reducing the production of uric acid. Gout is an inflammatory disease of joints caused by the deposition of monosodium urate crystals in the joint space. This occurs when serum concentrations of urate exceed the urate saturation point, which is approximately 0.42 mmol/L at 37°C [1, 2] . Unlike the widely used hypouricaemic drug allopurinol, febuxostat is not a purine analogue.
The aim of this review is to examine the pharmacokinetics of febuxostat and the relationships between dose, plasma concentrations, metabolism and hypouricaemic response to the drug. While there are currently considerable data from clinical trials on the effect of febuxostat, most studies on its pharmacokinetics and metabolism have been conducted in healthy subjects rather than the target population.
Chemistry
Febuxostat is a weak acid ( Fig. 1 ) with an acid dissociation constant (pKa) of 3.3. It follows that febuxostat is highly ionised at the pH of blood. The logarithm of the partition coefficient (logP) of the un-ionised form between octanol and water is 3.52. Thus, the un-ionised form is highly lipid soluble. These physicochemical properties are typical of many acidic drugs and are generally associated with high absorption, strong binding to plasma proteins and a low to moderate volume of distribution. Febuxostat is sparingly soluble in water, slightly soluble in methanol, freely soluble in N,N-dimethylformamide and sparingly soluble in ethanol. Febuxostat is not chiral (Fig. 1) .
Pharmacokinetics

Patterns of Plasma Concentrations in Healthy Subjects
Febuxostat is relatively rapidly absorbed after oral administration and reaches maximum (peak) plasma concentrations (C max ) after between 0.5 and 1.5 h under fasting conditions [2] . There is a substantial, approximately 100-fold, fall from C max to trough plasma concentrations during multiple dose administration when the dosage interval is 24 h (Fig. 2 ) [2] . Once-daily administration is the standard dosage regimen of febuxostat. The semi-logarithmic plots show a biphasic decline in plasma concentrations (Fig. 2) . Over the first 8 h, there is an approximately ten-fold fall in the plasma concentrations of febuxostat. In the next 16 h, the plasma concentrations decline further by approximately ten-fold. The biphasic pattern is not seen after daily doses of less than 40 mg because of the limit of the sensitivity of the assay (Fig. 2a ).
Pharmacokinetic Parameters
Published pharmacokinetic parameters of febuxostat have been determined by standard non-compartmental methods [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . The cited pharmacokinetic parameters are mean values of the apparent oral clearance (CL/F), volume of distribution at steady state (V ss /F) and elimination half-life (t ) ( Table 1) . We derived the overall mean and standard deviation of these pharmacokinetic parameters at steady state (Table 1 ) using the method of Sheiner et al. [12] (Eq. 1):
Overall mean parameter value
where P is the mean parameter value in each study, N is the number of healthy subjects in each study and w is the relative weighting of several studies. For the present calculations, no relative weighting could be determined, and the simplified Eq. 2, is thus applied:
In our calculation of the overall mean of the t of febuxostat, we did not include data reported for low doses (\40 mg) as the limit of quantification of the assay was not sufficient for the examination of the terminal phase (Fig. 2a ).
Modelling
The time course of mean plasma concentrations follows a bi-exponential pattern and a two-compartment model was used to fit the data (Fig. 1b) . The concentration (C) in plasma at time t is then given by the following equation (Eq. 3):
where a, b and k a are rate constants and A and B are concentration terms. Concentration time courses from the study of Khosravan et al. [2] at steady state were fitted using Minim 3.0.8 [13] together with the biexponential Eq. 3 (Table 2 ; Fig. 2 ). In the dose range of 40-240 mg, the calculated area under the plasma concentration-time curve (AUC) from time zero to 24 h (AUC 24 ) values were similar to those reported by Khosravan et al. [2] (Table 2 ) using non-compartmental methods.
Population Pharmacokinetic Analysis
Population pharmacokinetic analyses of the time course of plasma concentrations have used both two-compartment [14] and one-compartment [15] models. Covariates of body weight and renal function were of small influence in the two-compartment model [14] . This model was characterised by a large residual coefficient of variation (71 %) with respect to the prediction of plasma concentrations of febuxostat. Surprisingly, a one-compartment model [15] was used in one pharmacokinetic study but visual inspection of the time course of plasma concentrations indicates biphasic elimination. Body weight, but not renal function, was a covariate in this latter model [15] .
Absorption
As described in Sect. 4.1, the absorption of febuxostat is rapid with C max values being observed at about 1.5 h. C max increases proportionally with dose within the dose range of 10-240 mg ( Table 1) . The absolute oral availability of febuxostat has not been directly determined as there is no intravenous formulation. Based on recovery of febuxostat and its metabolites in urine and faeces, the oral availability is at least 75 % if we assume that the oxidative metabolites excreted in the faeces are derived from febuxostat that had been absorbed (Sect. 4.9). Based on an estimate of the CL/ F of febuxostat from whole blood, the oral availability is about 85 % (Sect. 4.8).
Distribution
Like many acidic drugs, febuxostat is highly bound (98-99 %) to plasma proteins, mainly to albumin [16] . As a result, febuxostat has a low to moderate V ss /F of 48 ± 23 L. The percentage absorption of febuxostat is approximately 85 % (Sect. 4.8) and, from the mean value of V ss /F, the real V ss /F is approximately 41 L. This volume of distribution is slightly less than the total body water and, consequently, the concentrations of febuxostat in the tissues are expected to be in equilibrium with the unbound concentrations in the plasma.
Half-Life
As noted earlier, febuxostat displays a biphasic elimination that is apparent at daily doses greater than 40 mg (Fig. 2) . The initial t is approximately 2 h and the terminal t is approximately 9.4 h ( Table 2 ). The short t values reported by the study of Khosravan et al. [2] (Table 1) following low doses represent those for the initial decline of the plasma concentrations of febuxostat, not a true terminal t . However, the bulk of the elimination of febuxostat occurs during the initial phase. This is indicated by area analyses in which the AUC from time zero to 8 h (AUC 8 ) comprises about 85 % of the total AUC 24 (Table 2 ; Fig. 2 ).
Clearance
The mean plasma CL/F of febuxostat is 10.5 ± 3.4 L/h (175 mL/min; Table 1 ). With a ratio of concentrations of 14 C-febuxostat in plasma to whole blood of 1.55 [4] , the CL/F of febuxostat from whole blood is about 16.3 L/h (270 mL/min). Assuming that oral availability of febuxostat is limited only by first-pass metabolism in the liver, the fraction of the dose absorbed (F) is given by Eq. 4 [17] :
where Q is the liver blood flow of 1500 mL/min and the CL/F of febuxostat from blood is 270 mL/min. Accordingly, the oral availability of febuxostat is approximately 85 %. This value is slightly greater than the Fig. 2 a Mean plasma concentration-time course of febuxostat following multiple oral dosing (od) to healthy subjects [2] ; and b time course of plasma concentrations at a dosage of 120 mg/day from the semi-log plots in a fitted using Minim 3.0.8 [13] . LLQ lower limit of quantification Mean and SD of parameters used in the calculation of the overall means and SD using the method of Sheiner et al. [12] percentage estimated from the renal and faecal recovery of febuxostat and its metabolites (Sect. 4.9). Factors other than hepatic first-pass metabolism that may have affected the calculated oral availability of febuxostat may include transport back into the intestine or metabolism in the lumen or within the intestinal wall. The CL/F value can be used to estimate the mean plasma concentration at steady state (C ss ) over a dosage interval as given by Eq. 5:
For instance, at a daily dose of 120 mg, the mean C ss is about 0.5 lg/mL. As is the case with many other drugs, the considerable variation in the CL/F of febuxostat (Table 1) indicates that there is large inter-patient variation in the plasma concentrations of febuxostat during multiple dose administrations. Adjustment of dosage according to response (effect on urate concentrations) must be an anticipated.
Metabolism and Excretion
Febuxostat is extensively metabolised in humans by phase I and II pathways. It is metabolised directly by glucuronidation (up to 40 %) [2, 4] mainly via uridine diphosphate-glucuronosyltransferase (UGT), namely UGT1A1, UGT1A8 and UGT1A9, forming the febuxostat acyl glucuronide [16] . UGT1A1 exhibits the highest overall activity for febuxostat acyl glucuronide formation followed by UGT1A8 and UGT1A9, while UGT1A3, UGT1A7 and UGT2B7 exhibit the lowest activity with respect to forming febuxostat glucuronide [16] . About 35 % of febuxostat is metabolised by oxidation [2, 4] via cytochrome P450 (CYP) 1A1, CYP1A2, CYP2C8 and CYP2C9 [16] (Fig. 1) .
Approximately 49 % of the total drug is recovered in the urine, while about 45 % is recovered in faeces over a period of 9 days [4] . About 30 % of the dose excreted in urine is the glucuronide of febuxostat, with a smaller amount being the parent drug (about 3 %) [4] . Of the dose, approximately 12 % is excreted as oxidative metabolites in urine [4] .
Approximately 25 % of the dose is excreted in faeces as the oxidised metabolites [4] and about 12 % as unchanged febuxostat [4] . The latter may represent unabsorbed material and/or drug that has been absorbed then excreted into the gastrointestinal tract via the bile as either the parent febuxostat or as the acyl glucuronide, which may subsequently be hydrolysed by gut bacteria. A proportion of this febuxostat may then be reabsorbed, a process known as enterohepatic cycling. Studies in mice [4] and the observation of multiple small secondary peaks in some individual plasma concentration-time profiles in humans [2] are the basis for this hypothesis. However, there are no direct studies to support such enterohepatic cycling in humans.
The systemic exposure to the three oxidative metabolites of febuxostat appears minimal compared with febuxostat [2] . At steady state following multiple administration with febuxostat to healthy subjects in the dose range 10-240 mg/day, the ratio of the AUC 24 of the three oxidative metabolites to that of febuxostat is an average of only about 0.08 [2] . However, the protein binding of the metabolites is unknown and the ratio of the unbound concentrations of the metabolites to unbound febuxostat is also unknown.
Characteristics and Pharmacokinetics of the Acyl Glucuronide
Acyl glucuronides of many drugs are readily cleared by the kidneys; however, they may accumulate when there is renal dysfunction. Subsequent hydrolysis may then regenerate the parent compound, which in effect reduces the overall CL/F of the parent drug. This process of glucuronidation and hydrolysis to release the parent drug is called 'futile cycling', which is a known feature of drugs that are cleared predominantly by forming acyl glucuronides [18] . It is not known to what extent this 'futile cycling' occurs with febuxostat and, therefore, how renal dysfunction may impact on its pharmacokinetics and pharmacodynamics. Furthermore, drug glucuronides are weak acids, and their secretion into the proximal renal tubules can be inhibited by probenecid [19, 20] . Probenecid may be used in conjunction with febuxostat in patients who do not achieve target serum urate but this combination has not been examined in systematic clinical studies (Sect. 9.2.2).
Several acyl glucuronides form protein adducts and have been putatively associated with adverse reactions such as hepatotoxicity [18] and immunogenic responses [21] . It is of note that hepatotoxicity and hypersensitivity to febuxostat have been reported during the clinical trials of febuxostat (Sect. 10.2) but it is not known whether the acyl glucuronide contributes to these toxicities.
Pharmacodynamics
In Vitro Pharmacodynamics
Febuxostat exhibits mixed-type competitive and uncompetitive inhibition of the two isoforms of the enzyme XOR [24, 25] . It acts as a structure-based inhibitor by filling the cavity (binding pocket or the substrate channel) of either isoform of XOR, thereby blocking access of the substrate to the active site. This is achieved by multiple chemical interactions with XOR, including hydrogen bonding, formation of salt bridges, hydrophobic interactions, p-p interactions and van der Waal interactions [24, 25] . The febuxostat-XOR complex, so formed, is independent of the redox-state of the molybdenum co-factor and is reported to be 'very stable' although the t of the complex has not been reported [24, 25] .
Febuxostat has IC 50 (concentration of drug producing 50 % inhibition) values of 1.4, 1.8 and 2.2 nmol/L using XOR in vitro from bovine milk, mouse liver and rat liver sources, respectively [26] . Following administration of febuxostat 40-120 mg/day in healthy subjects, the C max values of unbound febuxostat are well above the IC 50 while the trough concentrations in the dose range 80-120 mg (Table 3 ) are similar to the IC 50 values.
The oxidative metabolites of febuxostat have in vitro potencies approximately equal to that of febuxostat [4] . However, the contribution of the metabolites to the in vivo effect of lowering serum urate is not clear as, while their total plasma concentrations are very low, their unbound concentrations are not known (Sect. 4.9). There are no data that indicate hypouricaemic activity of febuxostat acyl glucuronide.
Febuxostat is selective for XOR. At concentrations up to 32 lg/mL (100 lmol/L), febuxostat has no effect on the activities of enzymes of purine and pyrimidine metabolism, namely guanine deaminase, hypoxanthine-guanine phosphoribosyltransferase, purine nucleoside phosphorylase, orotate phosphoribosyltransferase and orotidine-5 Vmonophosphate decarboxylase [27] .
Hypouricaemic Effects of Febuxostat in Healthy and Gouty Subjects
Several clinical studies have shown that febuxostat has hypouricaemic effects in normouricaemic and hyperuricaemic subjects (Fig. 3 ) [2, [28] [29] [30] [31] [32] [33] [34] . In healthy subjects, the maximal effect of febuxostat is an approximately 80 % reduction in serum urate at a daily dose of 240 mg [2, 28] and the ED 50 , the dose of febuxostat that reduces urate by 50 % of the maximum, is about 30-40 mg [2, 35] . Doses in excess of 120 mg do not provide significant additional C max maximum (peak) plasma concentration, C min trough plasma concentration Fig. 3 Percentage decrease in serum urate concentrations (mean and 95 % confidence interval) following multiple dosing in healthy volunteers with febuxostat 10-240 mg (adapted from Khosravan et al. [2] ) and 80 mg [7] and in gouty patients with febuxostat 10-20 mg [50] , 120 mg [31] and 240 mg [34] ) reduction of serum urate in normouricaemic subjects [28, 36] . In gouty patients, the percentage reductions of serum urate achieved are somewhat lower than those seen in healthy subjects (Fig. 3) . The maximal effect of febuxostat is about a 66 % reduction of serum urate at a daily dose of 240 mg (Table 4 ; Fig. 3 ) [34] , while the ED 50 (34 mg [37] and 41 mg [38] ) that reduces serum urate by 50 % is very similar to that seen in healthy subjects. The smaller percentage effect in patients with gout correlates with the higher baseline concentrations of urate [31] . In general, the percentage reductions of serum urate with febuxostat in gouty patients are very variable, with a coefficient of variation of up to 40 % (Table 4 ). This means that dose individualisation is required to achieve target serum urate values.
The general target for serum urate in the treatment of gout is 0.36 mmol/L [39] or lower (0.30 mmol/L) in patients with tophi [39] . Some clinical researchers suggest the target to be generally less than 0.30 mmol/L [40] . Although febuxostat is an effective hypouricaemic agent, many patients do not reach the goal of \ 0.36 mmol/L at the widely used doses of 80-120 mg (Table 4) . However, it is probable that some patients will achieve serum urate concentrations between 0.36 and 0.42 mmol/L, which may be sufficient to prevent further attacks of acute gout. If the concentrations of serum urate are not reduced to target concentrations, the dosage of febuxostat may be increased up to 240 mg daily (while recognising that there appears to be a ceiling to the maximum effect of febuxostat, as discussed earlier in this section) or combinations with uricosuric agents can be considered (Sect. 9.2.2). However, escalating the dose of febuxostat up to 240 mg daily, although used in clinical studies, may be limited by the maximal approved doses in various countries (up to 120 mg/day).
It appears that the once-daily dosages of febuxostat (40-120 mg) are sufficient to maintain hypouricaemic effects throughout the day. In patients with gout, an IC 50 of about 0.24 lg/mL has been estimated [14] . With approximately 1.5 % unbound, as discussed in Sect. 4.6, the unbound IC 50 value of febuxostat in gouty patients is, therefore, 3.6 ng/mL (11.3 nmol/L). This in vivo IC 50 value of unbound febuxostat is about five-to ten-fold the IC 50 values determined in vitro (Sect. 5.1) and is well above the trough plasma concentrations of unbound febuxostat following the once-daily dosages (40-120 mg; Table 3 ).
Time Courses of Hypouricaemic Effects of Single Doses in Normouricaemic Subjects
After single doses given to healthy subjects, febuxostat reduces serum urate in a dose-dependent manner in the dose range of 40-240 mg, with a maximum decrease of 40 % (Fig. 4) [35] . The hypouricaemic effect after single doses of febuxostat decreases over 24 h [35, 41] and lags well behind the time course of the plasma concentrations of the drug [35] (Figs. 2, 4) . The lag probably reflects more the time for removal of preformed urate than any delay between the concentrations of febuxostat at its site of action and its plasma concentrations [42] .
Time Courses of Hypouricaemic Effects Following Multiple Doses
In contrast to single doses, serum urate concentrations appear to be constant throughout the day after multiple dose administration with febuxostat [5, 11] . In healthy volunteers, it takes about 4 days for serum urate concentrations to achieve steady state [5, 7, 41] . In gouty patients, target serum urate concentrations of 0.36 mmol/L are achieved within 7 days [32].
Comparative Hypouricaemic Effects of Febuxostat and Allopurinol
Clinical studies comparing the hypouricaemic effects of febuxostat and allopurinol are summarised in Table 4 . In large-scale clinical studies, febuxostat (40 mg daily) has a similar hypouricaemic efficacy to allopurinol (300 mg daily) but higher doses of febuxostat (80-240 mg daily) have greater hypouricaemic activity than this dose of allopurinol (Table 4 ) [29-31, 33, 34] . In clinical practice, the daily dosage of allopurinol can be increased above the usual dosage of 300 mg daily, up to 900 mg daily [43] , to achieve target serum urate [44] [45] [46] . The relative efficacy of febuxostat has not been evaluated at the higher daily doses of allopurinol. Topiroxostat is a third XOR inhibitor that is now available but so far only in Japan.
Effect of Disease States on The Pharmacokinetics and Pharmacodynamics of Febuxostat
Renal Impairment
There are conflicting data in the literature as to the effect of renal function on the pharmacokinetics of febuxostat (Table 5) . Renal impairment would not be expected to affect the clearance of febuxostat since very little unchanged drug (about 3 %) is excreted renally. However, as noted in Sect. 4.10, febuxostat acyl glucuronide, like some other drug acyl glucuronides [18] , may undergo 'futile cycling' that regenerates the parent drug because of retention of the acyl glucuronide in renal impairment. The Table 4 Comparative hypouricaemic effects of febuxostat and allopurinol in clinical trials There is controversy concerning the effect of renal impairment on the response to febuxostat. One study concluded that renal function increased the proportion of patients achieving the target serum urate concentration [29] , although the relationship lacks a consistent pattern as a function of renal impairment (Table 4) [29, 47] . In contrast, the majority of the pharmacodynamic studies do not support an effect of renal function on response in terms of the percentage reduction of serum urate (Table 5) .
Overall, the effect of poor renal function on the pharmacokinetics and response to febuxostat is unclear. Patients with moderate to severe renal impairment (creatinine clearance \60 mL/min) make up about 40 % of patients with gout [53] . Further studies are warranted to better understand the effects of a range of renal function on the pharmacokinetics and/or pharmacodynamics of febuxostat at different dose levels.
Mild to Moderate Hepatic Impairment
There are no differences in the plasma pharmacokinetic parameters of febuxostat between normal subjects and those with mild or moderate hepatic impairment [6] . However, the mean percentage changes in serum urate values for subjects with mild or moderate hepatic impairment were lower, but only by about 13-14 %, than for subjects with normal hepatic function (p = 0.003). Interestingly, there is no difference in serum urate reduction between those with mild and those with moderate hepatic Fig. 4 Time course of serum urate concentrations in healthy subjects after single oral doses of febuxostat [35] . In comparison, the plasma concentrations of febuxostat are shown in Fig. 2 after multiple dosages. However, there is very little accumulation of febuxostat during multiple-dose administration and the time course of serum urate in this figure can be compared with that of febuxostat in Fig. 2 impairment. Febuxostat has not been evaluated in patients with severe hepatic impairment.
Effect of Age and Sex on the Pharmacokinetics and Pharmacodynamics of Febuxostat
The pharmacokinetic parameters of febuxostat in the elderly (C65 years) are similar to those seen in young subjects (18-45 years) [10] . Accordingly, the hypouricaemic effects are also similar in these two groups. In females, there is an increase in systemic exposure to unbound febuxostat that leads to a slightly greater reduction of serum urate than in males (59 vs. 52 %; p \ 0.01). This change is, however, not considered to be clinically meaningful.
Effect of Race on the Pharmacokinetics and Pharmacodynamics of Febuxostat
The CL/F of febuxostat is lower in healthy Chinese [8, 11] than in American subjects (Table 1) . This difference is reduced, however, after normalising the CL/F to body weight [8] . Healthy [41] and gouty Chinese [49] subjects achieved comparable percentage reductions of serum urate to those seen in healthy [2, 7] and gouty populations [29] from America. Polymorphisms of UGTs, CYPs and urate transporters are expected in different racial groups but there is presently no information on the genetic factors affecting the response to febuxostat.
Effect of Food and Other Drugs on the Pharmacokinetics and Pharmacodynamics of Febuxostat
Food
In healthy subjects, food (high-fat breakfast) was reported to reduce the C max values of febuxostat by nearly 50 % while the AUC 24 was decreased by about 20 % following either single (40 and 120 mg) or multiple dosing (80 mg) of febuxostat [5] . The C max was seen at about 2 h after a meal [5] . By contrast, when plasma concentrations were followed for 48 h, no overall effect of food on the AUC from time zero to 48 h (AUC 48 ) was reported [8] . In any event, there was no clinically relevant difference in the effect of multiple dosing with febuxostat 80 mg on urate concentrations whether fasted or fed in the former study [5] .
Drug Interactions
In Vitro Studies
Febuxostat in concentrations up to 32 lg/mL (100 lmol/L) has no effect on the CYP isoenzymes CYP1A2, CYP2C9, [16] . Interaction with the oxidation of other drugs is, therefore, unlikely to be clinically relevant.
In Vivo Studies
The in vivo interactions with concomitant therapies are summarised in Table 6 . Almost all the examined combinations produce clinically insignificant interactions. An exception is the combination of febuxostat and lesinurad, a uricosuric agent, which showed greater reductions of serum urate with the combination than with febuxostat alone (Table 6 ). Importantly, all of the patients achieved concentrations of serum urate below the target of 0.30 mmol/L [54] . Similar reductions of serum urate are probable with other uricosuric drugs such as lesinurad [55, 56] and probenecid [57] ; both potentiate the hypouricaemic response to allopurinol. When examining the effect of the drugs on the response of serum urate to febuxostat, it is important that the study is continued sufficiently until serum urate has achieved steady state. The t of serum urate is about 36 h in patients with gout [58] . Thus, steady-state serum urate is approached after about 6 days and the interaction study must be continued for at least this period. A single dose of hydrochlorothiazide decreases the reduction of serum urate during treatment with febuxostat by 8 % over 48 h [3] . Although this is not of clinical significance, there could be a greater interaction during long-term combined treatment with the two drugs.
Safety and Tolerability of Febuxostat
Adverse Events
Febuxostat is relatively well-tolerated, with the most frequent adverse effects being diarrhoea, nausea, dizziness, headache, liver function abnormalities, rash and musclerelated adverse events such as cramps and twitches [31, 34] . These adverse events are mild to moderate in severity and their incidences are low [29, 31, 34] .
An increase in thyroid-stimulating hormone (TSH) concentrations ([5.5 lIU/mL) with treatment with febuxostat (5.5 %) was reported [62] . This effect was evaluated prospectively for a year in a small cohort of patients taking febuxostat (n = 88) and allopurinol (n = 87) [63] . It was suggested that this may be a class effect of XOR inhibitors [63] . About 8 and 4 % of subjects treated with febuxostat AUC ? area under the plasma concentration-time curve from time zero to infinity, AUC 24 area under the plasma concentration-time curve from time zero to 24 h, CI confidence interval, CL/F apparent oral clearance, C max maximum (peak) concentration, CYP cytochrome P450, PKs pharmacokinetics, t max time to maximum (peak) concentration and allopurinol, respectively, showed raised TSH levels with no effect on free T4 and, consequently, this side effect may not be of any clinical relevance [63] . As with allopurinol, gout flares after initiation of febuxostat are common and thought to be due to disruption of the urate pool in the affected joints. This effect is more evident because the starting dose with febuxostat is large [31] . Concurrent prophylaxis during initiation of uratelowering therapy (particularly in the first 6 months) with a non-steroidal anti-inflammatory, colchicine or a corticosteroid is recommended [64] .
Hazards and Safety Signals
Hepatotoxicity has been reported in randomised controlled trials and in post-marketing reports with a latency period from starting febuxostat treatment that ranges from 2 to 55 weeks [65] [66] [67] . It is recommended that liver function be monitored at baseline and on development of symptoms that may indicate liver injury, and that febuxostat should be ceased if alanine aminotransferase (ALT) is more than three times the upper limit of normal [65] .
Concerns about increased cardiovascular events, including cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, were raised from the controlled clinical trials [31, 34] . Risk factors among these patients for these events include a history of cardiovascular disease and/or risk factors for developing cardiovascular disease [33] . Largescale clinical trials [68, 69] are underway to assess the cardiovascular safety of febuxostat versus allopurinol in patients with established cardiovascular disease. Monitoring for signs and symptoms of myocardial infarction and stroke should be considered in those with background risks.
Severe immunological reactions (e.g. Stevens-Johnson syndrome) have been reported in patients taking febuxostat [70] [71] [72] . These reactions seem to occur early after initiating treatment. Interestingly, the majority of these patients also had a history of allopurinol hypersensitivity and/or renal impairment.
Thirteen cases of agranulocytosis have been reported [73] and two cases of neutropenia were described in the literature with the initiation of febuxostat 10 mg daily for treatment of hyperuricaemia in patients with chronic kidney disease and other co-morbidities [74] . The authors postulated that the presence of human leukocyte antigen (HLA) alleles may be associated with an increased risk of neutropaenia [74] .
Some adverse events seen with febuxostat, such as cardiovascular events, liver toxicity, hypersensitivity and agranulocytosis, also occur for allopurinol [43] . It is not known whether it is the inhibition of XOR that triggers these events.
Conclusions
The place of febuxostat in the treatment of gout remains uncertain. It is an option for patients who do not tolerate allopurinol, although there may be some overlap between those who experience adverse effects for each drug. However, the majority of the pharmacokinetic studies of febuxostat have been conducted in healthy volunteers rather than in patients with gout. The drug is subject to large inter-subject variability in its pharmacokinetics and in the reduction in serum urate. The pharmacokinetics of this drug are changed by certain drug-drug interactions but the effect of these interactions on response is unknown.
The relationship between the dose, concentrations and response to febuxostat in patients with renal impairment is uncertain. In addition, the contribution of 'futile cycling' and the disposition of the acyl glucuronides and, more generally, to the pharmacokinetics and/or response to febuxostat are unknown.
There are conflicting data on the dose-concentrationresponse relationships in hepatic impairment. In this population, the pharmacokinetics of febuxostat are not affected by mild to moderate hepatic impairment but there is a small decrease in the hypouricaemic effect of febuxostat. Additional studies in gouty patients with hepatic impairment are needed. In addition, it remains to be established whether, in the setting of normal long-term usage in gouty patients, febuxostat is any more effective than allopurinol when both are titrated to achieve target urate concentrations.
The majority of the case reports on safety issues have insufficient information to assess and establish a causal link with febuxostat, particularly in view of co-morbidities and co-therapies. In an effort to gain a better insight into the risk-benefit profile of febuxostat, further research is required to investigate the possible underlying causes of these signals.
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